Premium
CD 43 expression is associated with inferior survival in the non‐germinal centre B ‐cell subgroup of diffuse large B ‐cell lymphoma
Author(s) -
Mitrovic Zdravko,
Iqbal Javeed,
Fu Kai,
Smith Lynette M.,
Bast Martin,
Greiner Timothy C.,
Aoun Patricia,
Armitage James O.,
Vose Julie M.,
Weisenburger Dennis D.,
Chan Wing C.
Publication year - 2013
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12356
Subject(s) - diffuse large b cell lymphoma , germinal center , lymphoma , subgroup analysis , stromal cell , immunostaining , medicine , cancer research , tissue microarray , b cell , pathology , biology , immunology , immunohistochemistry , antibody , meta analysis
Summary We evaluated the prognostic significance of CD 43 ( SPN ), a membrane glycoprotein, in 140 patients with diffuse large B ‐cell lymphoma ( DLBCL ) by tissue microarray ( TMA ) immunostaining, and gene expression profiling ( GEP ) in 43 patients. CD 43 protein was expressed in 19% of the cases and was strongly related to the non‐germinal centre B ‐cell (non‐ GCB ) subgroup by both TMA and GEP . Patients with CD 43(+) DLBCL had an inferior 3‐year overall survival ( OS ) compared to those with CD 43(‐) DLBCL (50% vs. 76%, P = 0·01). Within the non‐ GCB subgroup, patients with CD 43(+) DLBCL had a particularly poor 3‐year OS (32% vs. 71%, P < 0·001). Gene set enrichment analysis within the activated B ‐cell subgroup revealed significant enrichment in the stromal‐1 signature in CD 43(−) cases. We conclude that CD 43 is an adverse prognostic marker in DLBCL , and is preferentially expressed in the non‐ GCB subgroup. The dismal outcome of CD 43(+) cases in the non‐ GCB subgroup may be explained, at least in part, by a less favourable microenvironment.